GlassScriptPhysician profile
Hiep Ngo
NPI 1497763536
$5,967.29
in general payments reported to CMS, 2019-2025
40 companies · $4,674 in 2025
The $4,674 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.95 · 2024: $1,275 · 2025: $4,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,864 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,864.35 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $622.55 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $586.40 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $572.50 | 2024-2025 | Ultomiris |
| Abbvie INC. | $414.81 | 2024-2025 | |
| Noctrix Health, INC. | $348.58 | 2025 | Nidra |
| Pfizer INC. | $311.61 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $264.30 | 2024-2025 | Ingrezza |
| Eisai INC. | $260.84 | 2024-2025 | |
| Lundbeck LLC | $248.14 | 2024-2025 | Vyepti |
| Biogen, INC. | $210.94 | 2024-2025 | Skyclarys, Vumerity |
| Janssen Biotech, INC. | $191.47 | 2025 | |
| Argenx US, INC. | $160.90 | 2024-2025 | Vyvgart Hytrulo |
| Boston Scientific Corporation | $134.22 | 2025 | General - Dbs |
| Lilly USA, LLC | $129.67 | 2024-2025 | Kisunla |
| Octapharma USA, INC. | $114.15 | 2024-2025 | Panzyga |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $113.00 | 2025 | Xeomin, Inbrija |
| Neurelis, INC. | $111.30 | 2024-2025 | Valtoco |
| Ucb, INC. | $108.83 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
| Emd Serono, INC. | $108.51 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.00 | 2025 | Rexulti |
| Csl Behring | $76.10 | 2025 | Hizentra |
| Acadia Pharmaceuticals INC | $74.75 | 2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $71.26 | 2025 | Rytary, Crexont |
| Vanda Pharmaceuticals INC. | $68.80 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $61.73 | 2025 | |
| Grifols USA, LLC | $57.97 | 2025 | Gamunex-C |
| Axsome Therapeutics, INC. | $52.21 | 2025 | Symbravo |
| Genentech USA, INC. | $49.54 | 2024 | Ocrevus, Ocrevus Zunovo |
| Mallinckrodt Hospital Products INC. | $46.05 | 2025 | Acthar |
| Jazz Pharmaceuticals INC. | $45.52 | 2025 | |
| Amgen INC. | $44.06 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $34.42 | 2025 | Wainua |
| Bridgebio Pharma, INC. | $31.85 | 2025 | Attruby |
| Ani Pharmaceuticals, INC. | $28.76 | 2025 | Purified Cortrophin Gel |
| Ipsen Biopharmaceuticals, INC | $27.36 | 2025 | Dysport |
| Life Molecular Imaging LTD | $21.53 | 2024 | Neuraceq |
| Averitas Pharma INC. | $21.34 | 2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $20.23 | 2024 | |
| Impel Pharmaceuticals LLC | $18.14 | 2025 | Trudhesa |
| Davol INC. | $17.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiep Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.